Abstract: New data have re-established the importance of anticoagulation of patients with ST segment elevation myocardial infarction (STEMI), both as an adjuvant to reperfusion therapy or in patients ineligible for reperfusion. Recent randomized trials have found newer agents to be superior to conventional unfractionated heparin. This article summarizes current understanding of the underlying pathophysiology of STEMI and provides a comprehensive review of emerging trial data for low molecular weight heparins, anti-factor Xa agents and direct thrombin inhibitors in this setting.
Introduction
The contemporary approach to a patient with ischemic-type chest pain is to categorize them as experiencing an acute coronary syndrome (ACS) with or without ST segment elevation. The assessment of the initial 12-lead electrocardiogram (ECG) is therefore of critical importance as the management strategy is different for each group (Antman et al 2004; Braunwald et al 2002) . Prompt identifi cation of patients with acute ST segment elevation myocardial infarction (STEMI) is vital if patients are to benefi t from contemporary management strategies. Over the last 3 decades, major advances in our understanding of the pathophysiological processes responsible for STEMI and its sequelae have allowed development of pharmacological therapies to target these different processes. Numerous large well designed randomized controlled trials have guided determination of ever superior management strategies and their increasing utilization has been associated with a corresponding steady decline in death from acute myocardial infarction (MI) (Goldberg et al 2004) .
Pathophysiology of STEMI
Complex infl ammatory mechanisms are now known to participate in all stages of coronary artery disease, from the initial development of the fatty streak, through progression to advanced atherosclerotic lesions causing angina pectoris, to plaque disruption and thrombus formation. Plaques vulnerable to disruption and rupture are frequently non-obstructive but have a large lipid-rich core and a high macrophage content leading to thinning of the fi brous cap (Moreno et al 1994; Davies 2000; Shah 2003) . Plaque rupture, which typically occurs at the edge or shoulder region, exposes the lipid core, leading to platelet adhesion and aggregation, activation of the coagulation cascade, and formation of a platelet rich thrombus. A key step in this process is activation of prothrombin to thrombin (factor IIa) which promotes the formation of fi brin, the protein which acts as a scaffold in stable thrombus. The fate of the thrombus then ranges from simple incorporation into the plaque, through subtotal artery occlusion, to fully occlusive thrombus formation (Corti et al 2003) , the latter typically presenting clinically as STEMI (DeWood et al 1980) .
Reperfusion strategies for STEMI
Where possible, the immediate treatment goal in STEMI is to disperse the thrombus thereby restoring coronary blood fl ow to the culprit artery (Antman et al 2004) in order to limit infarct size, to preserve left ventricular function, and ultimately, to reduce mortality.
Two decades on from the landmark GISSI trial with streptokinase, fi brinolytic therapy remains the most widely used reperfusion strategy (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI) 1986). Second and third generation fi brinolytic agents interact directly with clot-bound plasminogen improving fi brin selectivity and achieve higher rates of early patency although this has translated at most into only a small further reduction in mortality. More important than the fi brinolytic agent used is the time delay from symptom onset to drug administration (Fibrinolytic Therapy Trialists' (FTT) Collaborative Group 1994; Boersma et al 1996) and hence the value of third generation bolus agents which help facilitate pre-hospital use.
Catheter based reperfusion with primary percutaneous coronary intervention (PCI) where available within a reasonable timeframe, may lead to even better reduction in cardiovascular events, except in patients who present very rapidly after symptom onset when both strategies appear to be equivalent (Keeley et al 2003; Steg et al 2003) . Primary PCI is associated with a reduced risk of bleeding complications, in particular intracranial hemorrhage (Keeley et al 2003) which typically occurs in approximately 1% of patients treated with a fi brinolytic based regimen. Trials have shown that the adjuvant anticoagulant dose may play a signifi cant role in the risk of intracranial hemorrhage (Giugliano et al 2001) .
Adjuvant antiplatelet therapy
The importance of adjuvant aspirin was established in ISIS-2 (ISIS-2 (Second International Study of Infarct Survival) Collaborative Group 1988) and the value of concurrent clopidogrel in the more recent CLARITY and COMMIT trials (Chen et al 2005; Sabatine et al 2005) . It is likely that their primary benefi t is to reduce reocclusion following successful reperfusion (Scirica et al 2006) . Initial trials of glycoprotein IIbIIIa receptor antagonists in combination with reduced dose fi brinolytic appeared promising, improving early patency and ST resolution (Antman et al 1999) . However the large GUSTO V trial found only a small effi cacy advantage in selected subgroups which was offset by a signifi cant increase in bleeding risk (Gurm et al 2004) .
Adjuvant anticoagulant therapy
While adjuvant anticoagulant therapy may give a small improvement in patency (Ross et al 2001) , like antiplatelet therapy, its main role is in helping to maintain patency after successful reperfusion. Additional potential benefi ts include prevention of deep venous thrombosis, pulmonary embolism and left ventricular thrombus. Current therapy choices include conventional unfractionated heparin (UFH) and newer agents, in particular low molecular weight heparin (LMWH), factor Xa inhibitors and direct thrombin inhibitors. The mechanism of action of these agents is illustrated in Figure 1 .
The guidelines mandate the concomitant use of anti-coagulant treatment with either pharmacological or mechanical reperfusion (Antman et al 2004) . An area of controversy has existed regarding the need of otherwise for anticoagulation with streptokinase as the latter induces prolonged fi brin depletion. Two meta-analyses, both published in 1996, failed to show evidence of clear benefi t with adjuvant UFH Mahaffey et al 1996) . However, more recent placebo controlled data have demonstrated benefi t for use of concomitant LMWH (Simoons et al 2002; Yusuf et al 2005) and factor Xa inhibition (Yusuf et al 2006) with streptokinase. Of note there is a paucity of placebocontrolled evidence for use of adjuvant anticoagulation with the fi brin-specifi c agents, or indeed primary PCI, mainly because of a presumption that anticoagulation use in these settings is clearly indicated.
Unfractionated heparin
Heparin is a heterogeneous mucopolysaccharide which interacts with antithrombin-III greatly increasing its inhibitory effects on thrombin (Hirsh and Fuster 1994) . The heparinantithrombin-III complex also has inhibitory effects on factor Xa and other clotting factors. Use of concurrent intravenous heparin has been shown to decrease early thrombin activity, improve culprit artery patency and reduce reocclusion, although the value of delayed subcutaneous (SC) heparin following fi brinolytic therapy is less clear (The GUSTO Angiographic Investigators 1993; Mahaffey et al 1996; Granger et al 1998) . A recent meta-analysis failed to show a clear benefi t for UFH compared to placebo (Eikelboom et al 2005) . A major drawback with UFH is the signifi cant variability in therapeutic response which occurs because of its heterogeneous composition and necessitates close New anticoagulant strategies in STEMI monitoring of the activated partial thromboplastin time (aPTT). The typical regimen for use in STEMI is an initial bolus of 60 U/kg (max 4000 U) and continued as an infusion of 12 U/kg/hr (max 1000 U/hr) for 48 hours adjusted to achieve an aPTT of 50-70 seconds. It is notoriously diffi cult to achieve and maintain the aPTT within this target range, and under-treatment is a signifi cant problem. In the TIMI 9B trial only approximately one third of patients had an aPTT within the target range at any given time, with between 25%-52% having sub-therapeutic levels (Antman et al 1996) . Ensuring that the aPTT does not rise above 70 seconds is of vital importance because, once exceeded, the absolute risk of intracranial hemorrhage rises in direct proportion to the aPTT . UFH can also give rise to an immunologically mediated thrombocytopenia known as heparin induced thrombocytopenia (HIT) which is rare but potentially life threatening. These drawbacks, together with the requirement for continuous intravenous (IV) administration, make UFH a less than ideal anticoagulant agent.
Low molecular weight heparin
LMWHs are approximately one third of the molecular weight of UFH, conferring greater bioavailability following subcutaneous administration (Antman 2001 Figure 1 Interaction of anti-thrombotic agents with coagulation cascade. UFH-antithrombin III complex has approximately equal inhibitory effects on factor Xa and IIa. LMWH-antithrombin III complex has greater relative specifi city for factor Xa. Pentasaccharide-antithrombin III complex acts only on factor Xa. Abbreviations: UFH, unfractionated heparin; LMWH, low molecular weight heparin; DTI, direct thrombin inhibitors. more convenient to administer in clinical practice. As well as improving bioavailability, once binding to antithrombin-III occurs, greater relative specifi city for factor Xa is provided when compared to UFH, producing enhanced blockade of the coagulation cascade upstream of thrombin generation. The ratio of inhibition of factor Xa:IIa varies between agents (for enoxaparin the ratio is 3:1) (Armstrong 1997) . HIT is less common with LMWH compared to UFH (Warkentin et al 1995) , but it is important to remember that, because LMWHs are made by depolymerisation of UFH, they can still give rise to this condition.
Placebo controlled studies with LMWH have confi rmed the importance of an adjuvant anticoagulant strategy. The AMI-SK study of 496 streptokinase treated MI patients showed that adjuvant enoxaparin compared with placebo improved early patency by 22%, improved early ST-segment resolution and was associated with a 36% reduction in the composite of death, reinfarction and recurrent angina (Simoons et al 2002) . The CREATE trial compared the LMWH reviparin with placebo in 15570 patients with STEMI (Yusuf et al 2005) , of whom 73% received fi brinolytic therapy and 6.1% underwent primary PCI, the remainder being treated conservatively. Reviparin signifi cantly reduced the composite endpoint of death, reinfarction and stroke although those receiving fi brinolytic therapy had an increased the risk of major bleeding including intracranial hemorrhage (0.4% vs 0.1% for reviparin and placebo groups respectively).
Enoxaparin has been extensively compared to UFH following fi brinolytic therapy for acute MI (see Table 1 ). Following early studies (Baird et al and HART II) , the ASSENT-3 trial randomized over 6000 patients receiving tenecteplase to full-dose tenecteplase and enoxaparin, half-dose tenecteplase with weight-adjusted low-dose UFH and a 12-hour abciximab infusion, or full-dose tenecteplase with 48 hours UFH (Assessment of the Safety and Effi cacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators 2001). Administration of enoxaparin with full dose tenecteplase led to signifi cant reductions in 30-day mortality, in-hospital reinfarction and in-hospital recurrent ischemia compared with UFH, with no signifi cant increase in overall bleeding.
However, the ASSENT-3 PLUS study of over 1600 prehospital patients (Wallentin et al 2003) showed an excess of intracranial hemorrhage with enoxaparin in patients >75 years, suggesting that a dose reduction was needed in this age group. The pivotal 20475 patient ExTRACT-TIMI 25 study (Antman et al 2006) thus compared UFH (standard bolus and 48 hour infusion) with a modifi ed enoxaparin regimen -standard 30 mg IV bolus then 1 mg/kg bd until hospital discharge, but reduced dose in patients ≥75 yrs (no initial IV bolus, SC dose reduced to 0.75 mg/kg) and a reduced frequency (once a day) in patients with impaired renal function. Median treatment duration with UFH was 2.0 days (interquartile range 2.0-2.2) and with enoxaparin was 7.0 days (interquartile range 4.5-7.5). Enoxaparin was associated with a 17% reduction in death or MI (9.9% vs 12%; p < 0.001), excess major bleeding (2.1% vs 1.4%) but no excess of intra-cranial hemorrhage (0.8% vs 0.7%; p = 0.14) and overall net clinical benefi t. Although it may be argued that ExTRACT was a comparison of treatment durations rather than drugs, even at 48 hours, the composite of death, MI and urgent revascularization was signifi cantly reduced with enoxaparin treatment (6.1% vs 5.3%; p = 0.02). Based on ExTRACT trial data, the Food and Drug Administation have formally approved enoxaparin for use in ST elevation MI.
A planned substudy of the ExTRACT trial (ExTRACT-PCI) evaluated whether enoxaparin was superior to UFH in those STEMI patients (almost a quarter of the total study cohort) who received thrombolytic therapy and subsequently underwent PCI within 30 days (Gibson et al 2007) . By 30 days, patients randomised to enoxaparin showed a 23% relative reduction in death or MI compared to UFH (10.7% vs. 13.8%; p = 0.001) without a signifi cant difference in the risk of major bleeding. Almost one half of the patients in this substudy underwent PCI while still receiving blinded study drug. Again, for this cohort, a reduction in 30 day death or MI risk was seen in the enoxaparin group compared to the UFH group (13.0% vs 16.7%; p = 0.013) without an increased risk of major bleeding.
Pentasaccharides
Pentasaccharides are manufactured to have a chemical structure similar to the antithrombin-III binding domain (active site) of heparin. Binding of pentasaccharide to antithrombin-III induces conformational changes leading to selective and potent inhibition of factor Xa resulting in greatly reduced thrombin generation (Coussement et al 2001) . Unlike UFH and LMWH there is no inhibitory effect on thrombin molecule itself. Pentasaccharides, such as fondaparinux, can therefore be considered as synthetic, highly selective, indirect inhibitors of factor Xa. Potential advantages of fondaparinux include 100% bioavailability after subcutaneous injection, a long half-life of 15-18 hours allowing for once daily administration, predictable anticoagulant effect with no requirement for monitoring, and no cross-reactivity with antibodies associated with HIT (Walenga et al 1997; Efi rd and Kockler 2006) . Also, selective and potent targeting of an upstream step in the coagulation cascade theoretically achieves superior anticoagulation as inhibition of one molecule of factor Xa reduces the downstream production of many molecules of thrombin (Antman 2001) . Table 2 summarizes the signifi cant results from the 2 clinical end-point trials which investigate fondaparinux use in STEMI patients.
The PENTALYSE study compared 5-7 days fondaparinux (4 mg, 8 mg, or 12 mg, initial dose IV then SC daily) with 48-72 hours UFH in 326 STEMI patients being treated with aspirin and alteplase (Coussement et al 2001) . There was no difference in early artery patency determined by 90 minute coronary angiography. Patients who did not have coronary intervention during the treatment period, showed a trend to less reocclusion with fondaparinux (repeat angiography day 5-7). PENTALYSE reported a trend to increased instrumental bleeding but no overall increase in hemorrhage.
The large multi-centre OASIS 6 trial (Yusuf et al 2006) is the fi rst large scale trial to report on the effi cacy and safety of fondaparinux in the setting of STEMI and therefore provides an extremely important extension of available evidence. It enrolled 12092 STEMI patients from 41 countries and randomized them in a complex design to fondaparinux (2.5 mg once daily for up to 8 days) or usual care which was defi ned as either placebo alone where UFH was not indicated (stratum 1, n = 5658), or UFH for up to 48 hours followed by placebo for up to 8 days in patients with an indication for UFH (stratum 2, n = 6434). The initial dose of fondaparinux was SC in stratum 1 and IV in stratum 2. The decision as to whether UFH was indicated was not predefi ned but based on the investigator's judgment. As with ExTRACT, it is important to note that stratum 2 was not only comparing 2 anticoagulants, but also 2 anticoagulation strategies. UFH was given for up to 48 hours only, while fondaparinux was given for up to 8 days. Fibrinolytic therapy was used in 45% of the patients (78.0% in stratum 1 and 15.9% in stratum 2), with streptokinase being the most commonly used (approximately 73%). Primary PCI was undertaken in 28.9% (0.2% in stratum 1 and 53.2% in stratum 2). Almost a quarter of patients (23.7%) did not receive any reperfusion therapy. The primary endpoint (death/re-MI) in stratum 1 patients was signifi cantly reduced by fondaparinux compared with placebo (11.2 vs 14.0; HR 0.79 [95% CI 0.68-0.92]). This adds to existing evidence (from AMI-SK and CREATE trials) confi rming adjuvant antithrombotic therapy is indicated along with fi brinolytic therapy, including streptokinase. In stratum 2 patients, there was no signifi cant reduction in the primary endpoint for fondaparinux compared with UFH (8.3 vs 8.7; HR 0.96 [95% CI 0.81-1.13]). Also of note, in patients undergoing primary PCI there was an increase in complications with fondaparinux compared with UFH including guide catheter thrombosis, abrupt coronary artery closure, new angiographic thrombus, or no refl ow. An interim protocol modifi cation advising additional UFH in fondaparinux patients undergoing acute PCI was thus required. Surprisingly, lower rates were observed for severe hemorrhage (44 vs 28; p = 0.06) and for major bleeds (57 vs 39; p = 0.07) with fondaparinux compared with placebo in stratum 1. This is in contrast to the CREATE trial which demonstrated a signifi cant excess of life-threatening bleeding in patients who received reviparin compared to placebo.
The reason for a reduction in major bleeding is not well understood -some suggesting it may be a consequence of better clinical outcome and/or reduced need for urgent revascularization. In stratum 2, the rates of severe and major bleeds were similar in the 2 groups.
Several conclusions can be drawn from the OASIS-6 trial. There is clear benefi t for fondaparinux in STEMI patients without an indication for UFH, where it is as safe as no anticoagulation. In conservatively managed STEMI patients with an indication for UFH who receive fi brinolytic therapy, fondaparinux is at least as effective and as safe as UFH. However, the use of fondaparinux as the sole anticoagulant for STEMI patients treated with primary PCI is associated with an increased risk of thrombotic complications, and thus pre-treatment with UFH before PCI is required.
Direct thrombin inhibitors
Unlike UFH, direct thrombin (factor IIa) inhibitors inactivate clot bound thrombin and prevent thrombin induced platelet aggregation. In the large GUSTO IIb trial (Metz et al 1998) 2274 patients treated with fi brinolytic therapy for STEMI were randomly assigned to the direct thrombin inhibitor hirudin or UFH. In patients receiving streptokinase, hirudin compared with UFH was associated with a reduction in 30 day death/re-MI (8.6% vs 14.4%; p = 0.004) although no difference was seen in patients treated with tissue-type plasminogen activator (see Table 3 ). In the HIT 4 study (Neuhaus et al 1999) , 1208 patients with STEMI were treated with aspirin and streptokinase and randomized to receive recombinant hirudin or heparin. A trend to earlier ST resolution was seen, but no difference in reinfarction, mortality or bleeding rates. A similar direct thrombin inhibitor, bivalirudin, showed improved early patency compared with UFH as an adjunct to streptokinase in the HERO study (White et al 1997) .
In the large 17073 patient HERO-2 study, bivalirudin as an adjunct to streptokinase did not reduce mortality at 30 days compared with UFH, but did reduce the rate of re-infarction within 4 days by 30% (White et al 2001) . It is noteworthy that, unlike ExTRACT and OASIS-6, this trial compared identical treatment durations of the anticoagulants under investigation (48 hour infusion). The advantage of bivalirudin over UFH in terms of reduced reinfarction came at the cost of a relatively small increase in moderate bleeding (1.4% vs 1.1%; p = 0.05). There was no signifi cant difference in the risk of severe bleeding. This fi nding of increased moderate bleeding is not consistent with previous trials (Kong et al 1999) . Again, more recently, bivalirudin has been associated with reduced bleeding compared with UFH plus antiplatelet glycoprotein IIb/IIIa inhibitors during early PCI for non-ST elevation acute coronary syndromes (Stone et al 2006) . It is currently being evaluated in the HORIZONS primary PCI STEMI trial, which is comparing bivalirudin to heparin plus glycoprotein IIb/IIIa inhibitor.
Summary and conclusions
The role of UFH in STEMI, particularly as an adjunct to fi brinolytic therapy, is being strongly challenged by the wealth of data surrounding newer anticoagulants including LMWH, factor Xa inhibitors and direct thrombin inhibitors. The evidence base is strongest for the LMWH enoxaparin where meta-analyses of multiple trials and the large ExTRACT trial have confi rmed that enoxaparin (doseadjusted for weight, renal function and age ≥75) compared with UFH, results in signifi cant net clinical benefi t. The recently published substudy of ExTRACT demonstrated superiority of enoxaparin over UFH in the patients who underwent PCI within 30 days of fi brinolytic therapy for STEMI, without a signifi cant difference in bleeding. The results of this study also suggest that for patients commenced on adjuvant enoxaparin after fi brinolytic therapy there is no need to switch to UFH if they proceed to PCI during the period of anticoagulation. Thus while based on current evidence, enoxaparin may be considered the anticoagulant of choice in STEMI, the factor Xa inhibitor fondaparinux suggests the intriguing possibility of further reduction in bleeding risk without loss of effi cacy. OASIS-6 has provided important data on 'real-world' use of fondaparinux, but because of the heterogeneous trial population and dependence on local investigator discretion to decide on the appropriateness of anticoagulant therapy, drawing fi rm conclusions for contemporary practice is diffi cult. Addi- tionally, given the increasing provision of early PCI after successful fi brinolysis or rescue PCI after failed fi brinolytic therapy, the excess of guide catheter thrombosis is an apparent limitation. While the direct thrombin inhibitor bivalirudin was associated with increased bleeding compared with UFH in HERO-2, more recent trials have focused on its potential as a substitute for UFH plus IIbIIIa inhibitors (and hence potential for reduced bleeding) during PCI. The ongoing HORIZONS trial will provide important data regarding bivalirudin's role in primary PCI. However as most STEMI patients continue to receive a primary fi brinolytic strategy, a head-to-head comparison of fondaparinux and bivalirudin with dose adjusted enoxaparin in a clearly-defi ned, fi brinolytic-treated population is eagerly awaited.
